Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INM004 for Prevention of HUS in Pediatric STEC
NCT04132375Phase 3Terminated
- Sponsor
- Inmunova
- Start
- Jul 2019
- Primary completion
- May 2022
- Modality
- Fab Fragments
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of equine immunoglobulin F(ab')2 fragments targeting Shiga toxin in hemolytic uremic syndrome (HUS) (5 arms), sponsored by Inmunova. Primary endpoint: Incidence of HUS development at 4 weeks. Started Jul 2019; status: terminated.
02
Drugs
equine immunoglobulin F(ab')2 fragments targeting Shiga toxin
03
Conditions
hemolytic uremic syndrome (HUS)
Beyond the preview
Go deeper on NCT04132375.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04132375.